Trial Profile
Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation (DAPA-AF) Prospective, Randomized, Multicenter, Placebo-Controlled Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Aug 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Acronyms DAPA-AF
- 09 Aug 2023 Status changed from active, no longer recruiting to completed.
- 07 Oct 2022 Time frame changed from 12 months to 6-12 months.
- 07 Oct 2022 Planned End Date changed from 1 Jun 2024 to 30 Jun 2023.